首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Pain reduction with oral methotrexate in knee osteoarthritis a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial
【2h】

Pain reduction with oral methotrexate in knee osteoarthritis a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial

机译:口服甲氨蝶呤治疗膝关节骨性关节炎的疼痛减轻这是一项实用的治疗效果III期试验(PROMOTE):一项随机对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundOsteoarthritis (OA) is the fastest growing cause of disability worldwide. Current treatments for OA are severely limited and a large proportion of people with OA live in constant, debilitating pain. There is therefore an urgent need for novel treatments to reduce pain. Synovitis is highly prevalent in OA and is associated with pain. In inflammatory arthritides such as rheumatoid arthritis, methotrexate (MTX) is the gold standard treatment for synovitis and has a well-known, acceptable toxicity profile. We propose that using MTX to treat patients with symptomatic knee OA will be a practical and safe treatment to reduce synovitis and, consequently, pain.
机译:背景骨关节炎(OA)是全球范围内增长最快的残疾原因。目前对OA的治疗受到严格限制,并且很大一部分OA患者生活在持续的使人衰弱的疼痛中。因此,迫切需要减轻疼痛的新疗法。滑膜炎在OA中高度流行,并伴有疼痛。在类风湿性关节炎等炎性关节炎中,氨甲蝶呤(MTX)是滑膜炎的金标准治疗方法,具有众所周知的可接受的毒性特征。我们建议使用MTX治疗有症状的膝骨关节炎的患者将是减少滑膜炎,从而减轻疼痛的实用且安全的治疗方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号